复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

休市中 01-02 16:08:46

19.950

+0.400

+2.05%

最高20.060	最低19.360	成交量98.05万
今开20.060	昨收19.550	日振幅3.58%
总市值530.47亿	流通市值107.92亿	总股本26.59亿
成交额1,938万	换手率0.18%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":19.95,"timestamp":1767341326004,"preClose":19.55,"halted":0,"volume":980500,"delay":0,"floatShares":540971500,"shares":2659000000,"eps":1.159187988748461,"marketStatus":"休市中","change":0.4,"latestTime":"01-02 16:08:46","open":20.06,"high":20.06,"low":19.36,"amount":19381913,"amplitude":0.035806,"askPrice":19.95,"askSize":3000,"bidPrice":19.94,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":1.3833497596191306,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":7,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":19.55,"dividendRate":0.017559,"openAndCloseTimeList":[[1767317400000,1767326400000],[1767330000000,1767340800000]],"volumeRatio":0.2532038318652247,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":26.49,"timestamp":1767164400000,"preClose":26.46,"halted":0,"volume":10401600,"delay":0,"premium":"-32.61"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2600036920","title":"每周股票复盘：复星医药（600196）SRT-007启动Ⅰ期临床，研发已投3219万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036920","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036920?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:59","pubTimestamp":1767293948,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，复星医药报收于26.89元，较上周的27.27元下跌1.39%。本周，复星医药12月22日盘中最高价报27.33元。该项目截至2025年11月累计研发投入约3,219万元。该药品尚需完成临床研究并经审批后方可上市，研发过程存在不确定性。股本股东变化截至2025年12月31日，复星医药普通股H股和A股的法定注册资本、已发行股份及库存股份数目均无变动。2025年A股期权计划项下88,700份期权失效，H股受限制股份单位计划下207,300份单位失效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600196","BK0012","BK0183","BK1191","BK1593","BK1515","BK0060","BK0196","BK0187","BK0096","BK0188","BK0028","BK0175","02196"],"gpt_icon":0},{"id":"2600837930","title":"上海复星医药2025年12月股份变动月报：A股期权与H股限制性股票单位计划实施中","url":"https://stock-news.laohu8.com/highlight/detail?id=2600837930","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600837930?lang=zh_cn&edition=full","pubTime":"2026-01-01 11:23","pubTimestamp":1767237788,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月31日提交了截至当月的股份变动月报表。报告显示，公司法定/注册股本及已发行股份总数在本月内均未发生变化。其中，A股法定/注册股本为人民币2,118,488,825元，对应股份数量为2,118,488,825股；H股法定/注册股本为人民币551,940,500元，对应股份数量为551,940,500股。同时，根据公司2025年H股受限制股份单位计划，本月有207,300份受限制股份单位失效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260101/31909972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0175","BK0096","02196","BK0060","BK0188","399300","BK0187","BK1515","BK1191","BK0196","159982","BK1593","BK0183","BK0239","600196","BK0012","BK0028"],"gpt_icon":0},{"id":"2595259720","title":"复星医药（600196）披露控股子公司药品临床试验进展，12月31日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595259720","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595259720?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:44","pubTimestamp":1767174262,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，复星医药报收于26.49元，较前一交易日上涨0.11%，最新总市值为707.4亿元。该股当日开盘26.48元，最高26.58元，最低26.31元，成交额达2.75亿元，换手率为0.49%。公司近日发布公告称，其控股子公司成都星睿菁烜生物科技有限公司在中国境内启动诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。该药品尚需完成临床研究并经审批后方可上市，研发过程存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100032601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","600196","BK1593","BK0012","BK0096","BK0175","BK0196","BK0028","BK0060","BK1515","BK0187","BK1191","02196","BK0188"],"gpt_icon":0},{"id":"1103911021","title":"复星医药（02196，600196）2025年12月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1103911021","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103911021?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:46","pubTimestamp":1767170787,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2025年12月31日发布2025年12月股份变动月报。公司H股及A股在报告期内均未发生新增发行、回购或注销等事项，股本结构整体保持稳定。截至2025年12月31日，H股注册股本为551,940,500股，A股注册股本为2,118,488,825股，合计法定注册股本为人民币2,670,429,325元。其中，已发行H股总数为540,971,500股，库存股为10,969,000股；已发行A股总数为2,098,582,573股，库存股为19,906,252股，均与上月保持一致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"gpt_icon":0},{"id":"2595788717","title":"每日卖空追踪 | 复星医药 12月31日卖空量成交4.85万股，卖空比例为5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595788717?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:30","pubTimestamp":1767169828,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月31日，跌0.1%，卖空量成交4.85万股，较上一交易日减少97.27%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163406a6e4c62c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163406a6e4c62c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2595783607","title":"ATR抑制剂研发困难重重，阿斯利康等大批药企已接连受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2595783607","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595783607?lang=zh_cn&edition=full","pubTime":"2025-12-31 13:41","pubTimestamp":1767159710,"startTime":"0","endTime":"0","summary":"近日，阿斯利康宣布，旗下ATR抑制剂Ceralasertib在Ⅲ期临床试验中未达到主要终点。据了解，近年来ATR抑制剂研发领域已遭遇了一系列重大挫折，除了阿斯利康重磅III期临床试验失败，还有不少药企因项目停滞或合作终止退出了这一赛道的竞争。如2023年，拜耳终止了其处于I期临床阶段的ATR抑制剂Elimusertib的研发。例如复星医药在2025年12月宣布，其自主研发的口服ATR抑制剂FXS0887片已获批开展针对晚期恶性实体瘤的I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231134259a48d2bdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231134259a48d2bdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","01276","BK1593","BK1515"],"gpt_icon":0},{"id":"2595713426","title":"港股公告掘金 | 云顶新耀：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713426","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595713426?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:55","pubTimestamp":1767106552,"startTime":"0","endTime":"0","summary":"重大事项：云顶新耀(01952)：原研产品耐赋康的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态联康生物科技集团(00690)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作和黄医药(00013)宣布赛沃替尼 (savolitinib) 用于治疗伴有MET扩增的胃癌患者的中国新药上市申请获受理并获纳入优先审评复星医药(02196)控股子公司就诊疗一体","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1588","BK1161","BK1593","02196","BK1191","00690","BK1587","00013","BK1515","BK1583","01952"],"gpt_icon":0},{"id":"2595795784","title":"复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2595795784","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595795784?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:03","pubTimestamp":1767088986,"startTime":"0","endTime":"0","summary":"12月30日，复星医药（600196/02196）发布公告，控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。该项目包括镓[68Ga]PSMA-0057（诊断）和镥[177Lu]PSMA-0057（治疗）两个注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605800274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","BK1593","BK0012","BK0028","BK0187","BK0239","BK0188","600196","SRT","BK4106","BK0183","BK4226","BK1515","BK0196","02196","BK0096","BK0175","BK1191"],"gpt_icon":0},{"id":"2595235767","title":"每日卖空追踪 | 复星医药 12月30日卖空量成交93.1万股，卖空比例为18.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595235767","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595235767?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:30","pubTimestamp":1767083427,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月30日，跌0.31%，卖空量成交93.1万股，较上一交易日减少13.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163409a4897ebd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163409a4897ebd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","02196","BK1515"],"gpt_icon":0},{"id":"2595723664","title":"推想携手直观复星，探索 AI赋能手术机器人场景的智能外科新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2595723664","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595723664?lang=zh_cn&edition=full","pubTime":"2025-12-30 15:46","pubTimestamp":1767080760,"startTime":"0","endTime":"0","summary":"近日，推想医疗与直观复星达成战略合作，聚焦外科诊疗“术前—术中”关键节点，探索AI在手术机器人场景的深度应用。双方将结合推想在AI三维重建与术前规划的能力，以及直观复星在手术机器人领域的系统平台优势，提升复杂外科手术的可视化水平与决策支持能力，为医生提供更具确定性的术前洞察，为手术机器人精准执行奠定高质量数据基础。通过AI融入外科术前环节，推想医疗助力医生获得更直观、可量化的解剖与病灶信息，提升手术方案制定的科学性与一致性。推想医疗创始人兼董事长陈宽表示，本次合作将推动AI无缝融入外科临床工作流，是智能微创外科的重要探索，期待与直观复星携手，让智能技术惠及更多临床场景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230155817a48957b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230155817a48957b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","02196","BK1515"],"gpt_icon":0},{"id":"2594024193","title":"每周股票复盘：复星医药（600196）拟控股投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2594024193","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594024193?lang=zh_cn&edition=full","pubTime":"2025-12-28 01:38","pubTimestamp":1766857092,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，复星医药报收于26.89元，较上周的27.27元下跌1.39%。本周关注点公司公告汇总：复星医药拟出资14.12亿元控股投资绿谷医药，标的公司主要产品甘露特钠胶囊已暂停生产和销售。公司公告汇总复星医药就控股投资绿谷医药事项回复上海证券交易所监管工作函。本次变动涉及吴中引导基金中心向吴中引导基金公司转让6,000万元基金份额，以及宁波复瀛向复星医药产业划转34,000万元基金份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0028","BK0239","BK0183","BK1161","BK0188","BK0012","600196","BK0060","02196","159938","BK1593","BK1515","BK1574","BK0175","BK0196","09939","BK0096","BK0187"],"gpt_icon":0},{"id":"2594236674","title":"比亚迪与复星达成全球战略合作 携手引领“出行+度假”新生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2594236674","media":"龙虎网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594236674?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:39","pubTimestamp":1766655594,"startTime":"0","endTime":"0","summary":"龙虎网讯 2025年12月18日，比亚迪与复星在江苏太仓阿尔卑斯国际度假区正式签署全球长期战略合作备忘录。比亚迪集团品牌及公关处总经理李云飞与复星全球合伙人、复星旅游文化集团首席执行官鲍将军代表双方签署合作备忘录。依托复星旅文旗下在全球40多个国家和地区运营的70余个高端度假目的地，双方将面向比亚迪全球超1500万车主与复星旅文复游会平台的全球2000万会员，共同打造专属权益体系，推动双方生态体系的深度互联。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225174048a4770ef9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225174048a4770ef9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0605514214.HKD","LU0516423091.SGD","LU1770034418.SGD","IE00BD6J9T35.USD","LU0417516738.SGD","81211","LU1251922891.USD","HYDD.SI","LU2360107325.USD","BK1504","LU0823426308.USD","LU2153592121.USD","LU0320764599.SGD","BK1119","LU0588545730.USD","LU2476274720.SGD","BK1509","LU0348767384.USD","LU0417516902.SGD","LU0359202008.SGD","LU2097828631.EUR","LU1242518931.SGD","LU2097828805.USD","LU0634319403.HKD","SG9999014674.SGD","LU0315178854.USD","LU0289961442.SGD","LU1868838027.USD","SG9999006597.SGD","LU1303224171.USD","BK1589","LU1880383440.USD","LU0449509016.USD","LU0359201612.USD","LU0594300179.USD","LU0269904917.USD","LU2357125470.USD","LU0561508036.HKD","LU2097828474.EUR","LU0511384066.AUD","01992","LU0516422952.EUR","LU0039217434.USD","LU2449936058.SGD","LU0165289439.USD","LU0540923850.HKD","LU0823039010.USD","LU1813983027.USD","LU0823038988.USD","LU1719994722.HKD","BK1539","LU2039709279.SGD","LU0164872284.USD","LU0572944931.SGD","LU0274383008.USD","SG9999001226.SGD","LU1242518857.USD","LU0348825331.USD","LU1808992512.USD","LU0594300419.USD","LU0531971595.HKD","LU2097828557.USD","LU2348774022.SGD","LU1794554557.SGD","BK1149","LU2097828714.EUR","LU0348805143.USD","LU0505663152.USD","SG9999002463.SGD","LU0516422366.SGD","LU0543330566.HKD","LU0359201885.HKD","LU0229945570.USD","LU0244354667.USD","LU0084288322.USD","002594","LU2294711713.HKD","LU0516423174.USD","BK1522","LU0449515922.USD","LU1868837565.USD","LU1861219969.SGD","SG9999015978.USD","LU0819121731.USD","LU1880383366.USD","BK1607","LU0143863784.USD","LU0588545904.SGD","LU1861214812.USD","SG9999006514.SGD","LU0175139822.USD","LU0254981946.USD","BK1540","LU0214875030.USD","LU1023057109.AUD","01211","LU0823414478.USD","LU0211977185.USD","LU0348766576.USD","LU0588545490.SGD","SG9999015945.SGD","LU0708995583.HKD","SG9999015986.USD","LU0593848301.USD","LU0326950275.SGD","LU0164865239.USD","LU0819123356.HKD","LU0289739343.SGD","LU1720050803.USD","LU0650527681.SGD","SG9999002828.SGD","LU1328277881.USD","LU0828238088.HKD","LU0823414551.USD","LU0856984785.SGD","LU0327786744.USD","LU0588546209.SGD","LU2506951792.HKD","LU0469268626.HKD","LU0531970944.HKD","LU0307460666.USD","LU0509642566.USD","02196","LU2399975544.HKD","LU0463099449.HKD","LU0314109678.HKD","LU2778985437.USD","BK1580","LU1188198961.HKD","LU0259732245.USD","LU0348735423.USD","BYDDY","LU2249611893.SGD","LU2476274308.USD","LU0054450605.USD","LU0516422440.USD","BK1610","LU0043850808.USD","BK1515","LU0979878070.USD","LU0052750758.USD","LU0143863198.USD","SG9999015952.SGD","BK1582","LU0289960550.SGD","BK1594","LU1868837722.USD","LU0871576103.HKD","LU0348827113.USD","LU0823426480.USD","LU0865486749.SGD","LU1961090484.USD"],"gpt_icon":1},{"id":"2594256088","title":"一家争议药企凭什么能卖14亿+？","url":"https://stock-news.laohu8.com/highlight/detail?id=2594256088","media":"动脉新医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594256088?lang=zh_cn&edition=full","pubTime":"2025-12-25 10:00","pubTimestamp":1766628043,"startTime":"0","endTime":"0","summary":"12月22日晚间，复星医药针对14.12亿元收购绿谷医药争议及上交所监管函作出回应，公告长达27页，内含上万字交易关键信息，披露了投资绿谷医药具体的交易方式、甘露特钠胶囊的研发投入与进展、交易风险是否可控及后续整合等市场关心的核心问题。截至9月30日，绿谷医药负债总额高达7.95亿元。意外的是，2022年5月，绿谷医药对外宣布提前终止这项试验。由于甘露特钠胶囊已停产超过1年，绿谷医药业绩堪忧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225100211a6cc7ed5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225100211a6cc7ed5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","09939","02196","BK1515","BK1161","BK1191","BK1574"],"gpt_icon":0},{"id":"2594770256","title":"复星医药将召开对外投资事项说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2594770256","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594770256?lang=zh_cn&edition=full","pubTime":"2025-12-25 05:30","pubTimestamp":1766611800,"startTime":"0","endTime":"0","summary":"中访网数据上海复星医药（集团）股份有限公司于2025年12月24日发布公告，宣布将就近期披露的对外投资事项召开投资者说明会。会议定于2025年12月30日15:00至16:00以视频结合网络互动的方式在上证路演中心平台举行。为提升沟通效率，公司已开放会前提问通道，投资者可在2025年12月25日至12月29日16:00期间，通过上证路演中心的“提问预征集”栏目或公司投资者关系邮箱提交问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225053023a474a86c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225053023a474a86c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","BK1593","02196"],"gpt_icon":0},{"id":"2593768604","title":"复星医药：募投项目结项","url":"https://stock-news.laohu8.com/highlight/detail?id=2593768604","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593768604?lang=zh_cn&edition=full","pubTime":"2025-12-24 18:05","pubTimestamp":1766570739,"startTime":"0","endTime":"0","summary":"南财智讯12月24日电，复星医药公告，截至2025年12月22日，公司2022年非公开发行募集资金已全部按承诺投入相关募投项目，专户中的募集资金（包括利息收入）已全部使用完毕，本次发行涉及的募投项目结项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600840925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0096","02196","BK0060","BK0188","BK0187","BK1515","BK1191","BK0196","BK1593","BK0183","BK0239","600196","BK0012","BK0028"],"gpt_icon":0},{"id":"2593413090","title":"复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413090","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593413090?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:08","pubTimestamp":1766498900,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，复星医药在互动平台回答投资者提问时表示，公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块，其中药品、器械及诊断产品的主要市场包括中国、美国、欧洲及新兴市场在内的多个国家和地区。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599787764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK0060","BK0183","01477","600196","BK1222","BK0187","BK1100","BK0096","XLV","09997","BK0012","BK0239","09996","BK1515","LABU","BK0028","XBI","BK1574","159883","BK1593","BK1191","BK0196","BK4585","BK4588","BK0188","BK4581","BK0175","BK1583","159760"],"gpt_icon":0},{"id":"2593459642","title":"复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459642","media":"中访网数据","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459642?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:00","pubTimestamp":1766419200,"startTime":"0","endTime":"0","summary":"中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。复星医药表示，此次收购旨在丰富其中枢神经系统疾病治疗领域的产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02196","BK1161","09939","BK1191","BK1593","BK1574"],"gpt_icon":0},{"id":"2593145964","title":"每日卖空追踪 | 复星医药 12月22日卖空量成交1.5万股，卖空比例为0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593145964","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593145964?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392229,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月22日，跌1.61%，卖空量成交1.5万股，较上一交易日减少95.69%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163433a6c09b6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163433a6c09b6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2593459625","title":"复星医药12月22日主力净流出355.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459625","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459625?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:16","pubTimestamp":1766391367,"startTime":"0","endTime":"0","summary":"12月22日, 复星医药股价跌1.61%，报收20.74元，成交金额4432.1万元，换手率0.39%，振幅2.28%，量比0.32。复星医药今日主力资金净流出355.9万元，上一交易日主力净流入272.3万元。该股近5个交易日下跌7.25%，主力资金累计净流出2813.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出242.5万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162427a4698853&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162427a4698853&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0},{"id":"2593431863","title":"复星万邦阿昔替尼片启动生物等效性试验 适应症为进展期肾细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2593431863","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593431863?lang=zh_cn&edition=full","pubTime":"2025-12-22 12:03","pubTimestamp":1766376180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，复星万邦（江苏）医药集团有限公司的阿昔替尼片在健康试验参与者中的随机、开放、两制剂、两序列、四周期、完全重复交叉设计、空腹和餐后状态下的生物等效性试验已启动。阿昔替尼片为化学药物，适应症为既往接受过一种酪氨酸激酶抑制剂或细胞因子治疗失败的进展期肾细胞癌的成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222132557a6bfea3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222132557a6bfea3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1230","02196","00656"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0278},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.246},{"period":"6month","weight":0.1908},{"period":"1year","weight":0.4825},{"period":"ytd","weight":0.0205}],"compareEarnings":[{"period":"1week","weight":0.0201},{"period":"1month","weight":0.0224},{"period":"3month","weight":-0.0296},{"period":"6month","weight":0.1013},{"period":"1year","weight":0.3422},{"period":"ytd","weight":0.0276}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.04621},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040467},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048431},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}